Literature DB >> 24462277

Hepatitis C virus core protein regulates NANOG expression via the stat3 pathway.

Jia-Jia Zhou1, Ru-Fu Chen2, Xiao-Geng Deng3, Yu Zhou3, Xiao Ye3, Min Yu3, Jing Tang3, Xiao-Yu He4, Di Cheng3, Bing Zeng3, Quan-bo Zhou2, Zhi-hua Li5.   

Abstract

HCV Core plays a role in the development of hepatocellular carcinoma. Aberrant expression of NANOG has been observed in many types of human malignancies. However, relationship between Core and NANOG has not been clarified. In this study, we found that Core is capable of up-regulating NANOG expression. Core-induced NANOG expression was accompanied by enforced expression of phosphorylated stat3 protein and was attenuated by inhibition of stat3 phosphorylation. ChIP showed that phosphorylated stat3 directly binds to the NANOG promoter. Core-induced NANOG expression resulted in enhanced cell growth and cell cycle progression. Knockdown of NANOG blocked the cell cycle at the G0/G1 phases and inhibited the cyclin D1 expression. Our findings provide a new insight into the mechanism of hepatocarcinogenesis by HCV infection.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hepatitis C virus core protein; Hepatocellular carcinoma; NANOG; Stat3 pathway

Mesh:

Substances:

Year:  2014        PMID: 24462277     DOI: 10.1016/j.febslet.2013.11.041

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  15 in total

Review 1.  NANOG: a promising target for digestive malignant tumors.

Authors:  Ai-Xi Sun; Chang-Jiang Liu; Zi-Qin Sun; Zhi Wei
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

2.  Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3.

Authors:  S Sengupta; A Nagalingam; N Muniraj; M Y Bonner; P Mistriotis; A Afthinos; P Kuppusamy; D Lanoue; S Cho; P Korangath; M Shriver; A Begum; V F Merino; C-Y Huang; J L Arbiser; W Matsui; B Győrffy; K Konstantopoulos; S Sukumar; P A Marignani; N K Saxena; D Sharma
Journal:  Oncogene       Date:  2017-06-05       Impact factor: 9.867

Review 3.  STAT3 activation in infection and infection-associated cancer.

Authors:  Rong Lu; Yong-Guo Zhang; Jun Sun
Journal:  Mol Cell Endocrinol       Date:  2017-02-20       Impact factor: 4.102

Review 4.  Regulation of NANOG in cancer cells.

Authors:  Shuai Gong; Qiuhui Li; Collene R Jeter; Qingxia Fan; Dean G Tang; Bigang Liu
Journal:  Mol Carcinog       Date:  2015-05-27       Impact factor: 4.784

5.  Stemness-related transcriptional factors and homing gene expression profiles in hepatic differentiation and cancer.

Authors:  Eman A Toraih; Manal S Fawzy; Abdullah I El-Falouji; Elham O Hamed; Nader A Nemr; Mohammad H Hussein; Noha M Abd El Fadeal
Journal:  Mol Med       Date:  2016-09-12       Impact factor: 6.354

Review 6.  The role of NANOG transcriptional factor in the development of malignant phenotype of cancer cells.

Authors:  Natalia Gawlik-Rzemieniewska; Ilona Bednarek
Journal:  Cancer Biol Ther       Date:  2016       Impact factor: 4.742

Review 7.  The Dynamic Interface of Viruses with STATs.

Authors:  Angela R Harrison; Gregory W Moseley
Journal:  J Virol       Date:  2020-10-27       Impact factor: 5.103

8.  Hepatocellular carcinoma: from hepatocyte to liver cancer stem cell.

Authors:  Ioannis Karakasiliotis; Penelope Mavromara
Journal:  Front Physiol       Date:  2015-05-18       Impact factor: 4.566

9.  Comparative Proteomics of Activated THP-1 Cells Infected with Mycobacterium tuberculosis Identifies Putative Clearance Biomarkers for Tuberculosis Treatment.

Authors:  Benjawan Kaewseekhao; Vivek Naranbhai; Sittiruk Roytrakul; Wises Namwat; Atchara Paemanee; Viraphong Lulitanond; Angkana Chaiprasert; Kiatichai Faksri
Journal:  PLoS One       Date:  2015-07-27       Impact factor: 3.240

10.  STAT3‑regulated long non‑coding RNAs lnc‑7SK and lnc‑IGF2‑AS promote hepatitis C virus replication.

Authors:  Yulin Xiong; Ming Jia; Jing Yuan; Changjiang Zhang; Yan Zhu; Xuemei Kuang; Lin Lan; Xiaohong Wang
Journal:  Mol Med Rep       Date:  2015-09-01       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.